BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

121 related articles for article (PubMed ID: 33853084)

  • 21. Mesenteric fibrosis and palliative surgery in small intestinal neuroendocrine tumours.
    Blažević A; Zandee WT; Franssen GJH; Hofland J; van Velthuysen MF; Hofland LJ; Feelders RA; de Herder WW
    Endocr Relat Cancer; 2018 Mar; 25(3):245-254. PubMed ID: 29255095
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Long-term results of surgery for small intestinal neuroendocrine tumors at a tertiary referral center.
    Norlén O; Stålberg P; Öberg K; Eriksson J; Hedberg J; Hessman O; Janson ET; Hellman P; Åkerström G
    World J Surg; 2012 Jun; 36(6):1419-31. PubMed ID: 21984144
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Clinical signs of fibrosis in small intestinal neuroendocrine tumours.
    Daskalakis K; Karakatsanis A; Stålberg P; Norlén O; Hellman P
    Br J Surg; 2017 Jan; 104(1):69-75. PubMed ID: 27861745
    [TBL] [Abstract][Full Text] [Related]  

  • 24. [Analysis of clinicopathological features of intestinal neuroendocrine neoplasms].
    Gao W; Liu SM; Lu HZ; Liang J; Yuan YL; Liu XY
    Zhonghua Zhong Liu Za Zhi; 2012 Jun; 34(6):450-6. PubMed ID: 22967448
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Midgut Neuroendocrine Tumors with Liver-only Metastases: Benefit of Primary Tumor Resection.
    Gangi A; Manguso N; Gong J; Crystal JS; Paski SC; Hendifar AE; Tuli R
    Ann Surg Oncol; 2020 Oct; 27(11):4525-4532. PubMed ID: 32394299
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Impact of Mesenteric Mass in Patients With Midgut Neuroendocrine Tumors.
    Malik P; Pinto C; Naparst MS; Ward SC; Aronson A; Aalberg JJ; Divino CM; Kim MK
    Pancreas; 2019; 48(5):682-685. PubMed ID: 31091215
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Preoperative
    Norlén O; Montan H; Hellman P; Stålberg P; Sundin A
    World J Surg; 2018 Feb; 42(2):498-505. PubMed ID: 29159606
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Role of Primary Tumor Resection for Metastatic Small Bowel Neuroendocrine Tumors.
    Hallet J; Law C;
    World J Surg; 2021 Jan; 45(1):213-218. PubMed ID: 32797281
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Extent of Lymph Node Dissection for Small Bowel Neuroendocrine Tumors.
    Hallet J; Law C;
    World J Surg; 2021 Jan; 45(1):197-202. PubMed ID: 32737557
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Clinicopathologic characteristics and prognosis of gastroenteropancreatic neuroendocrine neoplasms: a multicenter study in South China.
    Fang C; Wang W; Zhang Y; Feng X; Sun J; Zeng Y; Chen Y; Li Y; Chen M; Zhou Z; Chen J
    Chin J Cancer; 2017 Jun; 36(1):51. PubMed ID: 28637502
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Prognostic Factors Associated With Progression for Advanced-Stage/G1 and G2 Small-Bowel Neuroendocrine Tumors After Multimodal Therapy: Experience From a Tertiary Referral Center.
    Khetan P; Oyewole F; Wolin E; Kim MK; Divino CM
    Pancreas; 2020 Apr; 49(4):509-513. PubMed ID: 32224719
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Hepatic surgery for metastases from neuroendocrine tumors.
    Sarmiento JM; Que FG
    Surg Oncol Clin N Am; 2003 Jan; 12(1):231-42. PubMed ID: 12735141
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Value of Tumor Growth Rate (TGR) as an Early Biomarker Predictor of Patients' Outcome in Neuroendocrine Tumors (NET)-The GREPONET Study.
    Lamarca A; Crona J; Ronot M; Opalinska M; Lopez Lopez C; Pezzutti D; Najran P; Carvhalo L; Franca Bezerra RO; Borg P; Vietti Violi N; Vidal Trueba H; de Mestier L; Schaefer N; Sundin A; Costa F; Pavel M; Dromain C;
    Oncologist; 2019 Nov; 24(11):e1082-e1090. PubMed ID: 30910869
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Resection of the primary tumor improves survival in patients with gastro-entero-pancreatic neuroendocrine neoplasms with liver metastases: A SEER-based analysis.
    Zheng M; Li Y; Li T; Zhang L; Zhou L
    Cancer Med; 2019 Sep; 8(11):5128-5136. PubMed ID: 31328428
    [TBL] [Abstract][Full Text] [Related]  

  • 35. HSP90 expression and early recurrence in gastroenteropancreatic neuroendocrine tumors: Potential for a novel therapeutic target.
    Gamboa AC; Ethun CG; Postlewait LM; Lopez-Aguiar AG; Zhelnin K; Krasinskas A; El-Rayes BF; Russell MC; Kooby DA; Staley CA; Cardona K; Maithel SK
    Surg Oncol; 2020 Dec; 35():460-465. PubMed ID: 33080545
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Survival and disease recurrence in patients operated for small intestinal neuroendocrine tumors at a referral hospital.
    Folkestad O; Wasmuth HH; Mjønes P; Fougner R; Hauso Ø; Fossmark R
    Surg Oncol; 2020 Dec; 35():336-343. PubMed ID: 32979699
    [TBL] [Abstract][Full Text] [Related]  

  • 37. [CT and MRI findings of primary hepatic neuroendocrine neoplasm].
    Li JK; Wang M; Yuan J; Song ZG
    Zhonghua Zhong Liu Za Zhi; 2017 Aug; 39(8):600-606. PubMed ID: 28835083
    [No Abstract]   [Full Text] [Related]  

  • 38. Impact of initial imaging with gallium-68 dotatate PET/CT on diagnosis and management of patients with neuroendocrine tumors.
    Crown A; Rocha FG; Raghu P; Lin B; Funk G; Alseidi A; Hubka M; Rosales J; Lee M; Kennecke H
    J Surg Oncol; 2020 Mar; 121(3):480-485. PubMed ID: 31853990
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Clinicopathological features and prognosis of gastroenteropancreatic neuroendocrine neoplasms in a Chinese population: a large, retrospective single-centre study.
    Zhang M; Zhao P; Shi X; Zhao A; Zhang L; Zhou L
    BMC Endocr Disord; 2017 Jul; 17(1):39. PubMed ID: 28705205
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Mesenteric tumour deposits arising from small-intestine neuroendocrine tumours are frequently associated with fibrosis and IgG4-expressing plasma cells.
    Roberts J; Gonzalez RS; Revetta F; Shi C
    Histopathology; 2018 Nov; 73(5):795-800. PubMed ID: 29943407
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.